戻る Agenda
Session 6: Application and Use of Machine Learning, Artificial Intelligence, Automation, and Technology in Pharmacovigilance
Session Chair(s)
Susan Kindig, JD, MD
Prior Executive Director, Medical and Drug Safety
United States
This session will discuss use cases for Analytical/traditional AI and Generative AI and analyze the opportunities for expanding its’ impact/use. We will look at the impact of digital health on pharmacovigilance and forces at play with it’s ongoing impact. Lastly, we will explore ChatGPT for Safety professionals.
Learning Objective : - Develop an understanding of the practical uses of Analytical and Generative AI in pharmacoviglinace
- Acquire targeted knowledge to evaluate and apply ChatGPT's capabilities within the context of safety operations
- Leave with a clear framework for assessing the impact of Digital Health on Pharmacovigilance, including its benefits and challenges
Speaker(s)
Digital Health: A BooM or Burden to Pharmacovigilance?
Sibel D. Guerler, MSc
Bristol-Myers Squibb Company, Switzerland
Head, Innovation, Partnerships & Process Optimization, WorldWide Patient Safety
Use cases for Analytical/traditional AI and Generative AI: Where are the opportunities?
Tracey Boone, MBA
AbbVie, United States
Director